VistaGen Therapeutics (NASDAQ: VTGN) — Perfil da empresa, notícias e dados financeiros
VistaGen Therapeutics develops new medicines for CNS diseases, focusing on quicker and more effective treatments.
VistaGen Therapeutics
VistaGen Therapeutics (NASDAQ:VTGN) is a biopharmaceutical company focused on developing new generation medicines for anxiety, depression, and other central nervous system (CNS) diseases. Operating from their base, the company is deeply involved in innovative projects, aiming to provide better treatment alternatives that can potentially offer quicker onset of effects, better efficacy, and fewer side effects compared to existing therapies. VistaGen's objectives revolve around harnessing the power of its proprietary technology to build a diverse pipeline of CNS product candidates. Their commitment to improving mental health and well-being positions them as a dedicated player in the biopharmaceutical field, tirelessly working towards groundbreaking solutions that could transform the landscape of psychiatric and neurological care.
Resumo
Operações
Produtos e/ou serviços de VistaGen Therapeutics
- PH94B nasal spray for social anxiety disorder, aiming to reduce symptoms without systemic exposure or sedative effects.
- PH10 nasal spray for major depressive disorder, designed to alleviate symptoms without systemic exposure.
- AV-101, an oral NMDA receptor glycine B antagonist, intended for treatment-resistant depression and other CNS disorders.
- Preclinical development of AV-101 for dyskinesia in Parkinson's disease, seeking to reduce involuntary movements without affecting dopamine levels.
- Collaborations to explore AV-101's potential in neuropathic pain, emphasizing non-opioid pain management solutions.
equipe executiva do VistaGen Therapeutics
- Shawn K. SinghPresident, CEO & Director
- Nick B. TresslerCFO & Treasurer
- Joshua S. PrinceChief Operating Officer
- Reid G. AdlerChief Legal Officer
- Elissa CoteChief Corporate Development & Strategy Officer
- Louis MontiSenior Vice President of Translational Neuroscience
- Angel S. AngelovChief Medical Officer
- Jessica R. HaskellVP, Associate General Counsel & Secretary
Últimas notícias sobre a VistaGen Therapeutics
Principais indicadores financeiros
Resultados divulgados pela VistaGen Therapeutics, em USD.
- Cap. de mercado
- 7,5 mi
- Receita (TTM)
- 2,5 mi
- P/L
- —
- LPA (diluído, TTM)
- -1.7
- Dividend yield
- —
- Margem de lucro
- 0.0%
| Fim do ano fiscal | Receita | Resultado operacional | Lucro líquido |
|---|---|---|---|
| 1,3 mi | -72,1 mi | -69,7 mi | |
| 486 mil | -56 mi | -51,4 mi | |
| 1,1 mi | -33 mi | -29,4 mi | |
| -227,3 mil | -59,3 mi | -59,2 mi |